CHANGEBLOCK
27.11.2023 11:32:27 CET | Business Wire | Press release
Changeblock, a global sustainability fintech company utilizing advanced data-systems and technologies to accelerate planet repair and protection activities through the generation and exchange trading of high-integrity environmental assets, such as carbon credits, today announced the appointment of Baroness Evans of Bowes Park, former leader of the UK House of Lords, as Senior Advisor, Policy & Ethics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123431705/en/
Baroness Natalie Evans of Bowes Park, former UK Cabinet Minister as Leader of the House of Lords and Senior Advisor, Policy and Ethics of Changeblock Limited. (Photo: Business Wire)
Trust and integrity are crucial for companies to monetize their planet repair and protect initiatives, and therefore crucial for credits to be adopted at the scale necessary towards achieving net-zero, Consequently, policy and ethics are major focus areas for Changeblock that require integration into the credit value chain. The appointment of Baroness Evans will significantly strengthen the Company’s efforts in this regard, and augments the work already being done with multiple standard and verification agencies.
Baroness Evans commented, “Reducing society’s environmental footprint is one of the most pressing challenges we as humanity are facing today, and tradeable offsets, such as credits, hold great promise towards delivering this. Their effectiveness will be impacted by how the companies in this eco-system engage with policy and policy makers.
“Ethics play an increasingly important role in credit integrity assessments and in investment decision making. Changeblock’s forward, strategic thinking, combined with their unique offering that meets such a critical need, make this an exciting opportunity. I look forward to working with Billy and the team and help Changeblock cement its leadership position as a critical net-zero infrastructure partner.”
Billy Richards, Changeblock CEO, stated, “We believe Baroness Evans is exceptionally well positioned to provide Changeblock with actionable insights, and help us strengthen our position as a critical infrastructure partner for credit generators, off-setters, investors and policy makers. I believe this appointment reflects the importance, integrity and quality of our offering, as well as the depth and strength of our network, and I am excited to be working on these important initiatives with Natalie as we expand our operations and help smooth the path to net-zero.”
Baroness Evans
Baroness Evans of Bowes Park is a Conservative member of the House of Lords. She was appointed a life peer in October 2014, and acted as Leader of the House of Lords and a member of the UK Government’s Cabinet from 2016 to 2022 - the longest serving Leader for 70 years. Between 2015 and 2016 she was a junior Government minister in the Department of Education, Department for Work and Pensions, and the Ministry of Justice. Before entering the Lords, Natalie held a variety of senior positions including CEO of the New Schools Network, Deputy Director of Policy Exchange, and Head of Policy at the British Chambers of Commerce.
Changeblock at COP28
Billy Richards and Baroness Natalie Evans from Changeblock will attend COP28 in Dubai. Changeblock is hosting a roundtable with leaders like David Greenall (KPMG), Jim Andrew (Pepsico), and Michael Terrell (Google), discussing AI analytics in carbon offsetting. The roundtable, titled “The Critical Role of Integrity in Carbon Credits and Offsets for Effective Planet Repair,” will explore sustainable carbon mitigation strategies.
About Changeblock
Changeblock creates global markets that make the creation and trade of environmental assets for individuals, businesses, and governments easy, affordable, transparent, secure, and environmentally responsible. The company is led by professionals with deep expertise in technology and environmental credits with a proven track record in building and delivering solutions that work in the real world, including members of the team that created the first carbon credit, and come from top global organisations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231123431705/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom